tember 1995, after achieving complete remission with combined chemotherapy. Cytogenetic analysis of bone marrow prior to BMT showed normal male metaphases, but the We report a patient who relapsed in a patella and knee joint after allogeneic bone marrow transplantation reverse-transcriptase polymerase chain reaction (RT-PCR) revealed the presence of the bcr/abl transcript indicating (BMT) for Ph chromosome-positive acute lymphoblastic leukemia. The patient complained of pain and swelling MRD. The patient received an allogeneic BMT from his HLA-identical brother on 11 October 1995. Pretransplant of knee joint 14 months post-BMT. Fluid from the knee joint included leukemic cells consistent with the immunconditioning consisted of fractionated total body irradiation (days Ϫ9 to Ϫ6; 3 Gy/day), thiotepa (days Ϫ5 and Ϫ4; ophenotype of blasts prior to BMT and also revealed the bcr/abl transcript by reverse-transcriptase polymerase 210 mg/m 2 /day), and cyclophosphamide (days Ϫ3 and Ϫ2; 2250 mg/m 2 /day). He also received GVHD prophylaxis chain reaction. Magnetic resonance imaging demonstrated an abnormal signal in the patella. Radiotherapy with methotrexate (day 1, 15 mg/m 2 /day; and days 3 and 6, 10 mg/m 2 /day) and cyclosporine (3 mg/kg/day by conto the localized extramedullary lesion was successful and no bone marrow relapse has been detected cytologtinuous infusion). He received 250 g/day of granulocyte colony-stimulating factor by continuous infusion beginning ically and cytogenetically to date. This case suggests that the physician should be aware of unusual relapse sites on day 1 to aid granulocyte recovery. His granulocyte count was Ͼ1000/l from day 16 and his platelet count was Ͼ3 of leukemia post-BMT. Keywords: Ph chromosome-positive acute lymphoblastic ϫ 10 4 /l from day 19. After tapering of cyclosporine, he developed acute GVHD involving liver and intestine on day leukemia; extramedullary relapse; bone marrow transplantation 64. Cyclosporine and prednisolone were administered beginning on day 75, to control acute GVHD. On day 105, a bone marrow aspirate revealed hematologic and cytogenetic remission including the disappearance of the bcr/abl In patients undergoing bone marrow transplantation (BMT) transcript. The patient developed extensive chronic GVHD during remission from acute leukemia, the risk of relapse treated with prednisolone. is less than 30%.
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/day), and cyclophosphamide (days Ϫ3 and Ϫ2; 2250 mg/m 2 /day). He also received GVHD prophylaxis chain reaction. Magnetic resonance imaging demonstrated an abnormal signal in the patella. Radiotherapy with methotrexate (day 1, 15 mg/m 2 /day; and days 3 and 6, 10 mg/m 2 /day) and cyclosporine (3 mg/kg/day by conto the localized extramedullary lesion was successful and no bone marrow relapse has been detected cytologtinuous infusion). He received 250 g/day of granulocyte colony-stimulating factor by continuous infusion beginning ically and cytogenetically to date. This case suggests that the physician should be aware of unusual relapse sites on day 1 to aid granulocyte recovery. His granulocyte count was Ͼ1000/l from day 16 and his platelet count was Ͼ3 of leukemia post-BMT. Keywords: Ph chromosome-positive acute lymphoblastic ϫ 10 4 /l from day 19. After tapering of cyclosporine, he developed acute GVHD involving liver and intestine on day leukemia; extramedullary relapse; bone marrow transplantation 64. Cyclosporine and prednisolone were administered beginning on day 75, to control acute GVHD. On day 105, a bone marrow aspirate revealed hematologic and cytogenetic remission including the disappearance of the bcr/abl In patients undergoing bone marrow transplantation (BMT) transcript. The patient developed extensive chronic GVHD during remission from acute leukemia, the risk of relapse treated with prednisolone. is less than 30%. 1 The major cause of relapse is the presOne year after BMT, RT-PCR analysis from bone marence of minimal residual disease (MRD) that has not row revealed the reappearance of the bcr/abl transcript, but responded to myeloablative therapy and/or to the immune other cytologic and cytogenetic tests indicated continuing response after a transplant. 2 Isolated extramedullary relapse complete remission. The patient complained of right knee after BMT is a well-recognized phenomenon and is generpain with slight swelling, heat and redness on 16 December ally associated with a good prognosis. 3 We describe the 1996. Despite treatment with anti-inflammatory agents, the case of an unusual site of leukemic relapse 14 months after symptoms of arthritis worsened. Physical examination BMT for Ph chromosome-positive acute lymphoblastic leurevealed progressive swelling of the knee joint with no kemia (Ph-ALL).
masses. X-ray examination of the right knee joint showed no destructive or osteolytic lesions. Aspiration of the joint fluid was performed on 3 February 1997. Cytopathologic Case report study of this showed immature cells which had a high nucleo/cytoplasmic ratio and apparent nucleolus. Immuno-A 28-year-old man was diagnosed in June 1995 with Ph phenotyping of these cells showed CD10, CD19, and HLA-ALL. He was admitted to our hospital for BMT in Sep-DR. In addition, the RT-PCR for bcr/abl transcript was positive. Relapse of Ph ALL in the knee joint was thus right patella, distal to the femur. Magnetic resonance imaging (MRI) demonstrated an abnormal signal in the including the patella. Characteristics of the blasts suggested that the relapsed leukemia derived from the original leukepatella (Figure 1 ). This was seen by low intensity weighted imaging in T1 and slight enhancement with contrast MRI. mia clone. Isolated extramedullary relapse after chemotherapy has The bone marrow remained morphologically and cytogenetically normal during this period, except for the bcr/abl been treated with radiotherapy, chemotherapy and BMT.
Colleselli et al and his group 7, 9 have reported that autologtranscript detectable by RT-PCR. Since localized extramedullary relapse was confirmed, the patient was treated with ous BMT may be appropriate for patients with early extramedullary relapse in ALL. In contrast, it has been demonradiotherapy (34 Gy) in March 1997. His symptoms gradually regressed without systemic chemotherapy. He substrated that there is no advantage of BMT for isolated extramedullary relapse, except in patients developing sequently received additional chemotherapy with cytosine arabinoside and mitoxantrone to prevent relapse at other relapses at sites other than the CNS and the testis. 8 Patients with extramedullary relapses after BMT are gensites.
erally treated with chemotherapy and/or radiation. It is likely that a second BMT as salvage therapy will be associated with significant morbidity and mortality. 3, 5 Because Discussion patients relapsing in a focal bone following BMT are rare, 10, 11 there is no definite treatment strategy. According Leukemic relapse commonly relates to the subtype of leukemia and disease status at the time of BMT. 4 Although to previous reports, patients with isolated extramedullary relapses have a higher response to therapy than those with bone marrow relapse is more common, extramedullary relapses in sites such as the testis and central nervous sysbone marrow relapses. 3, 5 In this case, the local manifestations of relapse could be controlled with radiation thertem (CNS) are often seen in patients with ALL.
3,5-8 It has been reported that relapse in a focal bone occurred in seven apy. Although the patient revealed no morphological or cytogenetic relapse in the bone marrow, systemic relapse out of 130 (5%) patients who received BMT for ALL. 5 In the present report, the patient complained of symptoms subsequently occurs in most patients who develop an isolated extramedullary relapse. Moreover, the presence of the such as arthritis and the site of relapse was a knee joint, bcr/abl transcript detected by RT-PCR in the bone marrow indicated MRD. Therefore, the patient was treated with additional chemotherapy after the local radiation therapy. However, a patient with relapsed Ph ALL still has a very poor prognosis. To eradicate MRD in bone marrow and reduce the risk of clinical relapse, adoptive immunotherapy such as donor lymphocyte transfusions 12 and/or more intensive chemotherapy should be considered.
It has been reported that predictive factors for successful treatment of relapse after BMT are a long interval between BMT and relapse, and isolated extramedullary relapse. 3 Thus, our patient seems to be in a relatively good prognosis group. Furthermore, it is possible that a graft-versus-leukemia (GLV) effect 13 secondary to the chronic extensive GVHD may contribute to reducing the risk of bone marrow relapse. However, isolated extramedullary relapse may occur at sites where a GVL effect does not occur.
In summary, we report a patient who developed an isolated extramedullary relapse 14 months after BMT for Ph ALL, with his knee joint fluid positive for leukemic cells. His symptoms resembled arthritis. Although the knee joint is an unusual site for leukemia relapse, one should be aware that joint symptoms can be caused not only by chronic GVHD but also by leukemia relapse in patients undergoing BMT.
